Superior immune responses induced by intranasal immunization with recombinant adenovirus-based vaccine expressing full-length Spike protein of Middle East respiratory syndrome coronavirus.
Identifieur interne : 000364 ( PubMed/Checkpoint ); précédent : 000363; suivant : 000365Superior immune responses induced by intranasal immunization with recombinant adenovirus-based vaccine expressing full-length Spike protein of Middle East respiratory syndrome coronavirus.
Auteurs : Myung Hee Kim [Corée du Sud] ; Hyun Jik Kim [Corée du Sud] ; Jun Chang [Corée du Sud]Source :
- PloS one [ 1932-6203 ] ; 2019.
Descripteurs français
- KwdFr :
- Adenoviridae (génétique), Adenoviridae (immunologie), Administration par voie nasale, Animaux, Anticorps neutralisants (immunologie), Cellules HEK293, Cellules cultivées, Coronavirus du syndrome respiratoire du Moyen-Orient (immunologie), Femelle, Glycoprotéine de spicule des coronavirus (génétique), Glycoprotéine de spicule des coronavirus (immunologie), Humains, Immunoglobuline A (immunologie), Infections à coronavirus (), Infections à coronavirus (immunologie), Souris, Souris de lignée BALB C, Spodoptera, Vaccination (), Vaccins synthétiques (génétique), Vaccins synthétiques (immunologie).
- MESH :
- génétique : Adenoviridae, Glycoprotéine de spicule des coronavirus, Vaccins synthétiques.
- immunologie : Adenoviridae, Anticorps neutralisants, Coronavirus du syndrome respiratoire du Moyen-Orient, Glycoprotéine de spicule des coronavirus, Immunoglobuline A, Infections à coronavirus, Vaccins synthétiques.
- Administration par voie nasale, Animaux, Cellules HEK293, Cellules cultivées, Femelle, Humains, Infections à coronavirus, Souris, Souris de lignée BALB C, Spodoptera, Vaccination.
English descriptors
- KwdEn :
- Adenoviridae (genetics), Adenoviridae (immunology), Administration, Intranasal, Animals, Antibodies, Neutralizing (immunology), Cells, Cultured, Coronavirus Infections (immunology), Coronavirus Infections (prevention & control), Female, HEK293 Cells, Humans, Immunoglobulin A (immunology), Mice, Mice, Inbred BALB C, Middle East Respiratory Syndrome Coronavirus (immunology), Spike Glycoprotein, Coronavirus (genetics), Spike Glycoprotein, Coronavirus (immunology), Spodoptera, Vaccination (methods), Vaccines, Synthetic (genetics), Vaccines, Synthetic (immunology).
- MESH :
- chemical , genetics : Spike Glycoprotein, Coronavirus, Vaccines, Synthetic.
- chemical , immunology : Antibodies, Neutralizing, Immunoglobulin A, Spike Glycoprotein, Coronavirus, Vaccines, Synthetic.
- genetics : Adenoviridae.
- immunology : Adenoviridae, Coronavirus Infections, Middle East Respiratory Syndrome Coronavirus.
- methods : Vaccination.
- prevention & control : Coronavirus Infections.
- Administration, Intranasal, Animals, Cells, Cultured, Female, HEK293 Cells, Humans, Mice, Mice, Inbred BALB C, Spodoptera.
Abstract
Middle East respiratory syndrome coronavirus (MERS-CoV) causes an acute and severe lower respiratory illness as well as vomiting, diarrhea, and renal failure. Because no licensed MERS-CoV vaccines are currently available, preventive and therapeutic measures are urgently needed. The surface spike (S) glycoprotein of MERS-CoV, which binds to the cellular receptor dipeptidyl peptidase 4 (DPP4), is considered as a major target for MERS-CoV vaccine development. Here, we designed recombinant replication-deficient adenovirus-based vaccines expressing the N-terminal domain (rAd/NTD) and receptor-binding domain (rAd/RBD) of the MERS-CoV S1 subunit and full-length Spike protein (rAd/Spike). We found that immunization with candidate vaccines via intranasal route induced S1-specific IgG antibodies and neutralizing antibodies against MERS spike pseudotyped virus. Especially, rAd/Spike induced the highest neutralizing antibody titer and the strongest cytokine-induced T cell responses among the three candidate vaccines. To compare the immune responses induced by different administration routes, rAd/Spike was administered via intranasal, sublingual, or intramuscular route. All these administration routes exhibited neutralizing effects in the serum. MERS-CoV-specific neutralizing IgA antibodies in the bronchoalveolar lavage fluid were only induced by intranasal and sublingual administration but not by intramuscular administration. Intranasal administration with rAd/Spike also created resident memory CD8 T cells in the airway and lung parenchyma. Taken together, our results showed that both the humoral and cellular immune responses are highly induced by rAd/Spike administration, suggesting that rAd/Spike may confer protection against MERS-CoV infection.
DOI: 10.1371/journal.pone.0220196
PubMed: 31329652
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:31329652Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Superior immune responses induced by intranasal immunization with recombinant adenovirus-based vaccine expressing full-length Spike protein of Middle East respiratory syndrome coronavirus.</title><author><name sortKey="Kim, Myung Hee" sort="Kim, Myung Hee" uniqKey="Kim M" first="Myung Hee" last="Kim">Myung Hee Kim</name><affiliation wicri:level="3"><nlm:affiliation>Graduate School of Pharmaceutical Sciences, Ewha Woman's University, Seoul, Republic of Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Graduate School of Pharmaceutical Sciences, Ewha Woman's University, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Kim, Hyun Jik" sort="Kim, Hyun Jik" uniqKey="Kim H" first="Hyun Jik" last="Kim">Hyun Jik Kim</name><affiliation wicri:level="3"><nlm:affiliation>Department of Otorhinolaryngology, Seoul National University College of Medicine, Seoul, Republic of Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Otorhinolaryngology, Seoul National University College of Medicine, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Chang, Jun" sort="Chang, Jun" uniqKey="Chang J" first="Jun" last="Chang">Jun Chang</name><affiliation wicri:level="3"><nlm:affiliation>Graduate School of Pharmaceutical Sciences, Ewha Woman's University, Seoul, Republic of Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Graduate School of Pharmaceutical Sciences, Ewha Woman's University, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2019">2019</date><idno type="RBID">pubmed:31329652</idno><idno type="pmid">31329652</idno><idno type="doi">10.1371/journal.pone.0220196</idno><idno type="wicri:Area/PubMed/Corpus">000478</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000478</idno><idno type="wicri:Area/PubMed/Curation">000478</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000478</idno><idno type="wicri:Area/PubMed/Checkpoint">000364</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000364</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Superior immune responses induced by intranasal immunization with recombinant adenovirus-based vaccine expressing full-length Spike protein of Middle East respiratory syndrome coronavirus.</title><author><name sortKey="Kim, Myung Hee" sort="Kim, Myung Hee" uniqKey="Kim M" first="Myung Hee" last="Kim">Myung Hee Kim</name><affiliation wicri:level="3"><nlm:affiliation>Graduate School of Pharmaceutical Sciences, Ewha Woman's University, Seoul, Republic of Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Graduate School of Pharmaceutical Sciences, Ewha Woman's University, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Kim, Hyun Jik" sort="Kim, Hyun Jik" uniqKey="Kim H" first="Hyun Jik" last="Kim">Hyun Jik Kim</name><affiliation wicri:level="3"><nlm:affiliation>Department of Otorhinolaryngology, Seoul National University College of Medicine, Seoul, Republic of Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Otorhinolaryngology, Seoul National University College of Medicine, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Chang, Jun" sort="Chang, Jun" uniqKey="Chang J" first="Jun" last="Chang">Jun Chang</name><affiliation wicri:level="3"><nlm:affiliation>Graduate School of Pharmaceutical Sciences, Ewha Woman's University, Seoul, Republic of Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Graduate School of Pharmaceutical Sciences, Ewha Woman's University, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author></analytic><series><title level="j">PloS one</title><idno type="eISSN">1932-6203</idno><imprint><date when="2019" type="published">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenoviridae (genetics)</term><term>Adenoviridae (immunology)</term><term>Administration, Intranasal</term><term>Animals</term><term>Antibodies, Neutralizing (immunology)</term><term>Cells, Cultured</term><term>Coronavirus Infections (immunology)</term><term>Coronavirus Infections (prevention & control)</term><term>Female</term><term>HEK293 Cells</term><term>Humans</term><term>Immunoglobulin A (immunology)</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Middle East Respiratory Syndrome Coronavirus (immunology)</term><term>Spike Glycoprotein, Coronavirus (genetics)</term><term>Spike Glycoprotein, Coronavirus (immunology)</term><term>Spodoptera</term><term>Vaccination (methods)</term><term>Vaccines, Synthetic (genetics)</term><term>Vaccines, Synthetic (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adenoviridae (génétique)</term><term>Adenoviridae (immunologie)</term><term>Administration par voie nasale</term><term>Animaux</term><term>Anticorps neutralisants (immunologie)</term><term>Cellules HEK293</term><term>Cellules cultivées</term><term>Coronavirus du syndrome respiratoire du Moyen-Orient (immunologie)</term><term>Femelle</term><term>Glycoprotéine de spicule des coronavirus (génétique)</term><term>Glycoprotéine de spicule des coronavirus (immunologie)</term><term>Humains</term><term>Immunoglobuline A (immunologie)</term><term>Infections à coronavirus ()</term><term>Infections à coronavirus (immunologie)</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Spodoptera</term><term>Vaccination ()</term><term>Vaccins synthétiques (génétique)</term><term>Vaccins synthétiques (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Spike Glycoprotein, Coronavirus</term><term>Vaccines, Synthetic</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Neutralizing</term><term>Immunoglobulin A</term><term>Spike Glycoprotein, Coronavirus</term><term>Vaccines, Synthetic</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Adenoviridae</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Adenoviridae</term><term>Glycoprotéine de spicule des coronavirus</term><term>Vaccins synthétiques</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Adenoviridae</term><term>Anticorps neutralisants</term><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term><term>Glycoprotéine de spicule des coronavirus</term><term>Immunoglobuline A</term><term>Infections à coronavirus</term><term>Vaccins synthétiques</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Adenoviridae</term><term>Coronavirus Infections</term><term>Middle East Respiratory Syndrome Coronavirus</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Intranasal</term><term>Animals</term><term>Cells, Cultured</term><term>Female</term><term>HEK293 Cells</term><term>Humans</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Spodoptera</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Administration par voie nasale</term><term>Animaux</term><term>Cellules HEK293</term><term>Cellules cultivées</term><term>Femelle</term><term>Humains</term><term>Infections à coronavirus</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Spodoptera</term><term>Vaccination</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Middle East respiratory syndrome coronavirus (MERS-CoV) causes an acute and severe lower respiratory illness as well as vomiting, diarrhea, and renal failure. Because no licensed MERS-CoV vaccines are currently available, preventive and therapeutic measures are urgently needed. The surface spike (S) glycoprotein of MERS-CoV, which binds to the cellular receptor dipeptidyl peptidase 4 (DPP4), is considered as a major target for MERS-CoV vaccine development. Here, we designed recombinant replication-deficient adenovirus-based vaccines expressing the N-terminal domain (rAd/NTD) and receptor-binding domain (rAd/RBD) of the MERS-CoV S1 subunit and full-length Spike protein (rAd/Spike). We found that immunization with candidate vaccines via intranasal route induced S1-specific IgG antibodies and neutralizing antibodies against MERS spike pseudotyped virus. Especially, rAd/Spike induced the highest neutralizing antibody titer and the strongest cytokine-induced T cell responses among the three candidate vaccines. To compare the immune responses induced by different administration routes, rAd/Spike was administered via intranasal, sublingual, or intramuscular route. All these administration routes exhibited neutralizing effects in the serum. MERS-CoV-specific neutralizing IgA antibodies in the bronchoalveolar lavage fluid were only induced by intranasal and sublingual administration but not by intramuscular administration. Intranasal administration with rAd/Spike also created resident memory CD8 T cells in the airway and lung parenchyma. Taken together, our results showed that both the humoral and cellular immune responses are highly induced by rAd/Spike administration, suggesting that rAd/Spike may confer protection against MERS-CoV infection.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31329652</PMID><DateCompleted><Year>2020</Year><Month>02</Month><Day>26</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>7</Issue><PubDate><Year>2019</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS ONE</ISOAbbreviation></Journal><ArticleTitle>Superior immune responses induced by intranasal immunization with recombinant adenovirus-based vaccine expressing full-length Spike protein of Middle East respiratory syndrome coronavirus.</ArticleTitle><Pagination><MedlinePgn>e0220196</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0220196</ELocationID><Abstract><AbstractText>Middle East respiratory syndrome coronavirus (MERS-CoV) causes an acute and severe lower respiratory illness as well as vomiting, diarrhea, and renal failure. Because no licensed MERS-CoV vaccines are currently available, preventive and therapeutic measures are urgently needed. The surface spike (S) glycoprotein of MERS-CoV, which binds to the cellular receptor dipeptidyl peptidase 4 (DPP4), is considered as a major target for MERS-CoV vaccine development. Here, we designed recombinant replication-deficient adenovirus-based vaccines expressing the N-terminal domain (rAd/NTD) and receptor-binding domain (rAd/RBD) of the MERS-CoV S1 subunit and full-length Spike protein (rAd/Spike). We found that immunization with candidate vaccines via intranasal route induced S1-specific IgG antibodies and neutralizing antibodies against MERS spike pseudotyped virus. Especially, rAd/Spike induced the highest neutralizing antibody titer and the strongest cytokine-induced T cell responses among the three candidate vaccines. To compare the immune responses induced by different administration routes, rAd/Spike was administered via intranasal, sublingual, or intramuscular route. All these administration routes exhibited neutralizing effects in the serum. MERS-CoV-specific neutralizing IgA antibodies in the bronchoalveolar lavage fluid were only induced by intranasal and sublingual administration but not by intramuscular administration. Intranasal administration with rAd/Spike also created resident memory CD8 T cells in the airway and lung parenchyma. Taken together, our results showed that both the humoral and cellular immune responses are highly induced by rAd/Spike administration, suggesting that rAd/Spike may confer protection against MERS-CoV infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Myung Hee</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Graduate School of Pharmaceutical Sciences, Ewha Woman's University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hyun Jik</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, Seoul National University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Jun</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-8423-5987</Identifier><AffiliationInfo><Affiliation>Graduate School of Pharmaceutical Sciences, Ewha Woman's University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>07</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007070">Immunoglobulin A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000256" MajorTopicYN="N">Adenoviridae</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000281" MajorTopicYN="N">Administration, Intranasal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007070" MajorTopicYN="N">Immunoglobulin A</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065207" MajorTopicYN="N">Middle East Respiratory Syndrome Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018411" MajorTopicYN="N">Spodoptera</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>02</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>07</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>7</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>7</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31329652</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0220196</ArticleId><ArticleId IdType="pii">PONE-D-19-05731</ArticleId><ArticleId IdType="pmc">PMC6645677</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>PLoS One. 2013 Dec 04;8(12):e81587</Citation><ArticleIdList><ArticleId IdType="pubmed">24324708</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Mucosal Immunol. 2018 Jul;11(4):1071-1078</Citation><ArticleIdList><ArticleId IdType="pubmed">29453412</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2013 Jun 29;381(9885):2265-72</Citation><ArticleIdList><ArticleId IdType="pubmed">23727167</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Immunology. 2015 Aug;145(4):476-84</Citation><ArticleIdList><ArticleId IdType="pubmed">25762305</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Emerg Infect Dis. 2016 Jan;22(1):49-55</Citation><ArticleIdList><ArticleId IdType="pubmed">26692185</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2014 May 30;32(26):3169-3174</Citation><ArticleIdList><ArticleId IdType="pubmed">24736006</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Protoc. 2014 Jan;9(1):209-22</Citation><ArticleIdList><ArticleId IdType="pubmed">24385150</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Int J Med Microbiol. 2003 Apr;293(1):3-15</Citation><ArticleIdList><ArticleId IdType="pubmed">12755363</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Exp Mol Med. 2015 Aug 28;47:e181</Citation><ArticleIdList><ArticleId IdType="pubmed">26315600</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2014 Oct 14;32(45):5975-82</Citation><ArticleIdList><ArticleId IdType="pubmed">25192975</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet Infect Dis. 2013 Sep;13(9):745-51</Citation><ArticleIdList><ArticleId IdType="pubmed">23782859</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Leukoc Biol. 2014 Feb;95(2):215-24</Citation><ArticleIdList><ArticleId IdType="pubmed">24006506</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7348-E7357</Citation><ArticleIdList><ArticleId IdType="pubmed">28807998</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Microbiol Mol Biol Rev. 2005 Dec;69(4):635-64</Citation><ArticleIdList><ArticleId IdType="pubmed">16339739</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Microbiol Rev. 2015 Apr;28(2):465-522</Citation><ArticleIdList><ArticleId IdType="pubmed">25810418</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2013 Jul;87(14):7790-2</Citation><ArticleIdList><ArticleId IdType="pubmed">23678167</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2018 Apr 27;92(10):</Citation><ArticleIdList><ArticleId IdType="pubmed">29514901</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2014 Apr 11;32(18):2100-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24560617</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2016 Jun 3;34(26):2982-2987</Citation><ArticleIdList><ArticleId IdType="pubmed">27083424</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virol J. 2015 Dec 22;12:222</Citation><ArticleIdList><ArticleId IdType="pubmed">26695637</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Adv Biochem Eng Biotechnol. 2012;127:187-219</Citation><ArticleIdList><ArticleId IdType="pubmed">22015728</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2013 Aug 8;500(7461):227-31</Citation><ArticleIdList><ArticleId IdType="pubmed">23831647</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2013 Nov;87(21):11950-4</Citation><ArticleIdList><ArticleId IdType="pubmed">23986586</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antiviral Res. 2016 Sep;133:165-77</Citation><ArticleIdList><ArticleId IdType="pubmed">27468951</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2012 Nov 8;367(19):1814-20</Citation><ArticleIdList><ArticleId IdType="pubmed">23075143</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Allergy Asthma Immunol Res. 2016 Jan;8(1):69-78</Citation><ArticleIdList><ArticleId IdType="pubmed">26540504</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Commun. 2015 Jul 28;6:7712</Citation><ArticleIdList><ArticleId IdType="pubmed">26218507</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Med. 2016 Jul 7;22(7):701-5</Citation><ArticleIdList><ArticleId IdType="pubmed">27387881</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Emerg Microbes Infect. 2017 May 24;6(5):e37</Citation><ArticleIdList><ArticleId IdType="pubmed">28536429</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antiviral Res. 2019 Mar;163:19-28</Citation><ArticleIdList><ArticleId IdType="pubmed">30639307</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2014 May 13;111(19):E2018-26</Citation><ArticleIdList><ArticleId IdType="pubmed">24778221</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2017 Apr 11;35(16):2069-2075</Citation><ArticleIdList><ArticleId IdType="pubmed">28314561</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Curr Opin Virol. 2014 Apr;5:58-62</Citation><ArticleIdList><ArticleId IdType="pubmed">24584035</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Viral Immunol. 2014 Dec;27(10):543-50</Citation><ArticleIdList><ArticleId IdType="pubmed">25387086</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2013 Mar 14;495(7440):251-4</Citation><ArticleIdList><ArticleId IdType="pubmed">23486063</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2016 Sep 3;388(10048):994-1001</Citation><ArticleIdList><ArticleId IdType="pubmed">27402381</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2014 Dec;88(23):13769-80</Citation><ArticleIdList><ArticleId IdType="pubmed">25231316</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2015 Aug;89(16):8651-6</Citation><ArticleIdList><ArticleId IdType="pubmed">26018172</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2017 Jan 3;35(1):10-18</Citation><ArticleIdList><ArticleId IdType="pubmed">27899228</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2019 Jan 4;93(2):</Citation><ArticleIdList><ArticleId IdType="pubmed">30404801</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Expert Opin Ther Targets. 2017 Feb;21(2):131-143</Citation><ArticleIdList><ArticleId IdType="pubmed">27936982</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>mBio. 2012 Nov 20;3(6):</Citation><ArticleIdList><ArticleId IdType="pubmed">23170002</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Emerg Infect Dis. 2013 May;19(5):736-42B</Citation><ArticleIdList><ArticleId IdType="pubmed">23693015</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2014 May;88(10):5209-12</Citation><ArticleIdList><ArticleId IdType="pubmed">24600003</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):4970-5</Citation><ArticleIdList><ArticleId IdType="pubmed">24599590</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Euro Surveill. 2012 Oct 04;17(40):20290</Citation><ArticleIdList><ArticleId IdType="pubmed">23078800</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Cell Res. 2013 Aug;23(8):986-93</Citation><ArticleIdList><ArticleId IdType="pubmed">23835475</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Curr Opin Virol. 2017 Apr;23:49-58</Citation><ArticleIdList><ArticleId IdType="pubmed">28412285</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS One. 2014 Nov 18;9(11):e112602</Citation><ArticleIdList><ArticleId IdType="pubmed">25405618</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>EBioMedicine. 2015 Aug 18;2(10):1438-46</Citation><ArticleIdList><ArticleId IdType="pubmed">26629538</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Hum Vaccin Immunother. 2016 Sep;12(9):2351-6</Citation><ArticleIdList><ArticleId IdType="pubmed">27269431</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2509-14</Citation><ArticleIdList><ArticleId IdType="pubmed">9482916</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Genome Announc. 2015 Aug 13;3(4):</Citation><ArticleIdList><ArticleId IdType="pubmed">26272558</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Commun. 2017 Apr 10;8:15092</Citation><ArticleIdList><ArticleId IdType="pubmed">28393837</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Sci Transl Med. 2015 Aug 19;7(301):301ra132</Citation><ArticleIdList><ArticleId IdType="pubmed">26290414</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>JCI Insight. 2016 Jul 7;1(10):</Citation><ArticleIdList><ArticleId IdType="pubmed">27468427</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2015 Sep 5;386(9997):995-1007</Citation><ArticleIdList><ArticleId IdType="pubmed">26049252</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):15214-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25288733</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS One. 2013 Oct 03;8(10):e76469</Citation><ArticleIdList><ArticleId IdType="pubmed">24098509</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2016 Jan 1;351(6268):77-81</Citation><ArticleIdList><ArticleId IdType="pubmed">26678878</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Exp Med. 2010 Jun 7;207(6):1153-60</Citation><ArticleIdList><ArticleId IdType="pubmed">20457758</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 2017 Jan 15;198(2):873-882</Citation><ArticleIdList><ArticleId IdType="pubmed">27903740</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Sci Rep. 2017 Mar 23;7:44875</Citation><ArticleIdList><ArticleId IdType="pubmed">28332568</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 2015 Jul 1;195(1):203-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26026054</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Corée du Sud</li></country><region><li>Région capitale de Séoul</li></region><settlement><li>Séoul</li></settlement></list><tree><country name="Corée du Sud"><region name="Région capitale de Séoul"><name sortKey="Kim, Myung Hee" sort="Kim, Myung Hee" uniqKey="Kim M" first="Myung Hee" last="Kim">Myung Hee Kim</name></region><name sortKey="Chang, Jun" sort="Chang, Jun" uniqKey="Chang J" first="Jun" last="Chang">Jun Chang</name><name sortKey="Kim, Hyun Jik" sort="Kim, Hyun Jik" uniqKey="Kim H" first="Hyun Jik" last="Kim">Hyun Jik Kim</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000364 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000364 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:31329652
|texte= Superior immune responses induced by intranasal immunization with recombinant adenovirus-based vaccine expressing full-length Spike protein of Middle East respiratory syndrome coronavirus.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:31329652" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |